BioTech 365

OCTOBER 5, 2021

SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio Rapid development of key mutation detection reagents continues to facilitate critical investigation and monitoring activities SYDNEY–(BUSINESS WIRE)–#COVID19–SpeeDx Pty.

Genotype 52

Genotype Reagent Development 52

The Pharma Data

SEPTEMBER 8, 2021

TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic. For example, in 2001 with anthrax and 2003 with SARS-CoV1, TIB Molbiol demonstrated their ability to develop PCR assays for the detection of new pathogens within days. About TIB Molbiol.

Genotype 52

Genotype Reagent Genetics Research 52

The Pharma Data

MARCH 16, 2022

It’s critical to quickly and accurately identify variants to inform ongoing research – including the ongoing development of therapeutics and vaccines. To support customers performing human genotyping, TIB Molbiol provides custom-made LightSNiP assays for SNP analysis. 2, as well as other mutations, present in the novel B.1.1.529

In-Vitro 52

In-Vitro Genotype Reagent Protein 52